FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell...

Exelixis, a biopharmaceutical company based in South San Francisco, CA, announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to cabozantinib as a potential treatment for patients with advanced...

Merck Receives Breakthrough Therapy Designation from U.S. FDA for KEYTRUDA® in Advanced Colorectal Cancer

Merck announced that the U.S. FDA has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Expands Site in the United States for Drug Development...

We are pleased to announce the grand opening of WuXi AppTec's expanded Laboratory Testing Division (LTD) facility in New Jersey. The expansion will double total...